Sequential sorafenib and regorafenib in patients with advanced HCC

Dr. Mohamed Bouattour discusses the recently published additional analyses from the phase 3 RESORCE trial on sequential treatment with sorafenib followed by regorafenib for hepatocellular carcinoma.